- Home
- ATNF vs ARTL Comparison
ATNF vs ARTL Comparison
Compare ATNF & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATNF
- ARTL
- Stock Information
- Founded
- ATNF 2016
- ARTL 2011
- Country
- ATNF United States
- ARTL United States
- Employees
- ATNF N/A
- ARTL N/A
- Industry
- ATNF Biotechnology: Pharmaceutical Preparations
- ARTL Biotechnology: Pharmaceutical Preparations
- Sector
- ATNF Health Care
- ARTL Health Care
- Exchange
- ATNF Nasdaq
- ARTL Nasdaq
- Market Cap
- ATNF 4.1M
- ARTL 3.6M
- IPO Year
- ATNF N/A
- ARTL N/A
- Fundamental
- Price
- ATNF $0.86
- ARTL $0.86
- Analyst Decision
- ATNF
- ARTL Strong Buy
- Analyst Count
- ATNF 0
- ARTL 2
- Target Price
- ATNF N/A
- ARTL $5.50
- AVG Volume (30 Days)
- ATNF 35.6K
- ARTL 13.9K
- Earning Date
- ATNF 05-14-2025
- ARTL 05-12-2025
- Dividend Yield
- ATNF N/A
- ARTL N/A
- EPS Growth
- ATNF N/A
- ARTL N/A
- EPS
- ATNF N/A
- ARTL N/A
- Revenue
- ATNF N/A
- ARTL N/A
- Revenue This Year
- ATNF N/A
- ARTL N/A
- Revenue Next Year
- ATNF N/A
- ARTL N/A
- P/E Ratio
- ATNF N/A
- ARTL N/A
- Revenue Growth
- ATNF N/A
- ARTL N/A
- 52 Week Low
- ATNF $0.90
- ARTL $0.86
- 52 Week High
- ATNF $17.75
- ARTL $1.60
- Technical
- Relative Strength Index (RSI)
- ATNF 36.88
- ARTL 40.75
- Support Level
- ATNF $0.90
- ARTL $0.91
- Resistance Level
- ATNF $1.02
- ARTL $1.04
- Average True Range (ATR)
- ATNF 0.07
- ARTL 0.04
- MACD
- ATNF 0.00
- ARTL -0.00
- Stochastic Oscillator
- ATNF 37.01
- ARTL 36.59
About ATNF 180 Life Sciences Corp.
180 Life Sciences Corp is a clinical-stage biotechnology company. It is focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis by employing innovative research, and, where appropriate, combination therapy.
About ARTL Artelo Biosciences Inc.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors and neurotransmitters that form a biochemical communication network in body. It is focused on discovering, licensing, developing, and commercializing treatments that control endocannabinoid systems. The company pursues technologies and programs that offer proprietary approaches to cannabinoid-based therapies, also those derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare and orphan disease.